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Abstract
Diabetic ketoacidosis (DKA) is a leading cause of morbidity and mortality in patients
with type 1 diabetes (T1DM). Individuals familiar with this complication of diabetes
should be able to identify the earliest signs and symptoms and act promptly to pre‐
vent further deterioration. However, even in patients with established diabetes, the
rates of DKA are considerable. This chapter discusses in detail the various aspects of
DKA in the pediatric population with T1DM. The prevalence and regional effects on
the prevalence of DKA as well as the specific risk factors, whether disease, patient, or
physician related, are reviewed. Patients with DKA experience a condition of starva‐
tion despite the abundance of metabolic substrate (i.e., glucose); the pathophysiologi‐
cal mechanisms responsible for the development of DKA are outlined. Next, a
detailed discussion of the clinical aspects of DKA is provided. This includes the clini‐
cal findings at presentation, the approach to treatment, and potential complications.
Prevention is the best method for reducing rates of DKA. Somewhat different factors
apply in patients with new-onset diabetes when compared with those with establish‐
ed diabetes and these are reviewed.
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1. Introduction
Diabetic ketoacidosis (DKA) is an acute life-threatening complication of type 1 diabetes
(T1DM). Despite our detailed knowledge of this condition, rates of occurrence both in new-
onset diabetes and in established diabetes are significant. This chapter will discuss various
aspects of DKA in the pediatric population with T1DM, ranging from epidemiology and
pathophysiology through the spectrum of clinical considerations, including the clinical
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presentation, diagnosis, treatment, and complications, and will end with a discussion of the
importance and means for prevention of DKA.
Chapter outline:
• Epidemiology of DKA in the pediatric population
• Pathophysiology of DKA
• Clinical presentation and diagnosis of DKA
• DKA Treatment in children
• Complications of pediatric DKA
• Prevention of pediatric DKA
• Conclusion
2. Epidemiology of DKA in the pediatric population
Despite our thorough understanding of the pathophysiology of this potentially life-threaten‐
ing complication of T1DM, DKA remains a relatively common occurrence in childhood
diabetes.
2.1. DKA at diagnosis of T1DM
2.1.1. DKA prevalence
The prevalence of DKA at T1DM diagnosis varies greatly worldwide and ranges between 13%
and 80% in different countries [1-11]. A large systematic review of 65 studies including over
29,000 children worldwide found that the lowest prevalences were reported in Sweden,
Canada, the Slovak Republic, and Finland and the highest prevalences in the United Arab
Emirates, Saudi Arabia, and Romania [1]. Latitude and the regional background incidence of
T1DM were negatively associated with the prevalence of DKA [1, 10, 12]. Increased incidence
of T1DM has previously been associated with more northern latitudes, although it is unclear
whether this represents a true environmental effect or rather reflects ethnic and racial varia‐
tions between populations [13, 14]. Taken together, these associations suggest that decreased
awareness to T1DM and related complications may be a risk factor for DKA at diabetes
diagnosis. To further support this, lack of a family history of diabetes was shown to increase
the risk of presenting with DKA at diabetes diagnosis [7, 15]. However, despite the increasing
incidence of T1DM around the world in recent decades [16], and therefore potentially increased
awareness, the prevalence of DKA at diagnosis appears to remain stable [5, 6, 9, 17]. Data from
the Search for Diabetes in Youth study (SEARCH), a multicenter US study, found that rates
remained stable during 8 years of follow-up for the whole pediatric group as well as when
assessing separately the younger children (<4 years of age) and the older children and [9]. They
also did not detect any significant gender or ethnicity-specific changes over time.
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2.1.2. Risk factors for DKA
The majority of data points to similar rates of DKA at diabetes diagnosis in boys and girls
worldwide [7, 9, 11, 12, 15] (Table 1). However, one study based in Germany did suggest a
slightly increased prevalence in girls [4] and another suggested increased prevalence in girls
when assessing the very young age-group, under 2 years of age [3]. A younger age at diabetes
diagnosis is consistently identified as an important risk factor related to DKA at presentation
[2, 3, 6, 7, 9, 15, 18]. In a systematic review of 46 studies involving 24,000 children worldwide,
younger age was found to be the most common factor associated with increased risk for DKA
at diabetes diagnosis [12]. Different age cutoffs between 2 and 5 years of age were used in
studies to describe this association. Odds ratios higher than 4 were found for Finnish children
under 2 years of age when compared to those 2 years or older [19, 20]. In the SEARCH study
increased prevalence of DKA at presentation was detected in children less than 4 years of age,
particularly when compared to youth 15–19 years of age [7]. The causes for this increased
prevalence in younger children are likely multiple. Younger children are more prone to
misdiagnosis when initially presenting with T1DM [21]. This can reflect a lower index of
suspicion on the physician’s side combined with the difficulty of identifying the classic
symptoms in a toddler; infants and young children might not be able to describe symptoms,
and findings may be similar to those of other acute illnesses. However, toddlers may actually
suffer a more aggressive progression of metabolic decompensation. There is evidence that
younger children have a shorter prodromal period [22] as well as a more rapid decline in beta
cell reserve after diabetes diagnosis [19, 23]. A lower BMI or weight loss have also been
associated with increased risk for DKA at diagnosis in a number of small studies [15, 24].
Children from ethnic minorities are at increased risk for DKA at T1DM onset [12]. In the United
States, higher rates of DKA at diagnosis have been recorded in Hispanic and African American
youth when compared with non-Hispanic white North-American youth [9]. In the UK,
children from an Asian background were at increased risk of presenting with DKA, particu‐
larly if under 5 years of age[11]. Another study from the UK demonstrated that children from
non-white ethnicity were at higher risk of a delayed T1DM diagnosis and that a delayed
diagnosis was associated with increased risk of DKA at presentation [25]. In the Israeli Negev,
the prevalence of DKA at diabetes diagnosis was significantly higher in the Bedouin minority
when compared to either the general population or the Jewish population [26]. In another
study from Israel, children from an Ethiopian origin had an increased prevalence of DKA at
presentation [15]. However, this is not supported by all studies, and others did not find a
predilection to minority groups [7, 27]. Another predictor of DKA is a lower socioeconomic
status [28]. Several components of the socioeconomic status have been identified as significant.
Lower household income was found in US and Canadian studies to be a risk factor [2, 7, 9];
however, European studies did not necessarily support this [29]. In the United States, lack of
private health insurance was also identified [7, 9, 30]. More years of parental education as well
as academic education of the parents were found protective [7, 31, 32]. However, even in the
more privileged populations, the rate of DKA at diagnosis of diabetes is substantial and
recorded to occur in over 20% of patients [7]. “Physician-dependent” factors may also increase
the risk for DKA at diabetes diagnosis. Such factors include delayed diagnosis of diabetes or
a missed diagnosis [25, 21], delayed presentation to secondary care, or delayed treatment after
T1DM diagnosis [10, 17].
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Risk factors for diabetic ketoacidosis at diabetes diagnosis
Patient specific Younger age
Ethnic minority
Lower socioeconomic status
Physician related Delayed diabetes diagnosis
Delayed initiation of treatment
Epidemiological Lower regional background prevalence of T1DM
Residence in a less northern latitude
Risk factors for recurrent diabetic ketoacidosis
Insulin omission and poor adherence to treatment
Poor metabolic control
Previous episodes of DKA
Behavioral and psychiatric disorders
Higher levels of family conflict
Lower socioeconomic status
Limited access to outpatient diabetes care
Table 1. Risk factors for diabetic ketoacidosis in the pediatric population
2.2. DKA in patients with established T1DM
Recurrent DKA is by large a preventable complication in patients with established T1DM. In
a large cohort of 1243 children with T1DM, the incidence of DKA in patients with established
T1DM was 8/100 person-years [33]. Another study assessing a large database of children with
established T1DM from Germany and Austria evaluated the incidence of DKA in the most
recent year of follow-up [34]. They found that 6% of children suffered from DKA, 5% had a
single episode, and 1% had two or more episodes. Two smaller studies followed children with
T1DM for about 8 years and found 20–28% to experience at least one episode of DKA [26, 35].
As reflected in these data, it is estimated that it is the same small proportion of patients (around
20%) that account for the majority of admissions for DKA [33, 36]. Insulin omission and poor
adherence to treatment are major risk factors [37] (Table 1). Poorer diabetes control, higher
hemoglobin A1c, higher insulin doses, and previous episodes of DKA are also important risk
factors [33, 34, 38]. Recurrent DKA episodes peak in teenage years, particularly in females [33,
34]. Moreover, the incidence of DKA was found to increase with age in females, yet remained
stable in males. A study evaluating the role of patient and family psychosocial functioning as
predictors of recurrent acute diabetic complications [35] found girls with recurrent DKA to
demonstrate lower social competence and higher rates of behavioral problems. The families
exhibited higher levels of family conflict and decreased family cohesion and organization.
Major psychiatric disorders have also been implicated in recurrent DKA [39]. As is the case in
DKA at T1DM diagnosis, lower socioeconomic status and limited access to outpatient diabetes
care are also predictors of recurrent DKA [39].
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3. Pathophysiology of DKA in children
By definition, hyperglycemia and ketoacidosis are the major components of DKA [40]. The
initial impairment leading to DKA is an absolute or relative insulin deficiency. The sequence
of events that follows leads to a patient that suffers hyperglycemia, dehydration, acidosis,
electrolyte deficiencies, and variable degrees of cerebral dysfunction [41] (Figure 1). In a patient
with new-onset diabetes, the cause for the insulin deficiency is the progressive deterioration
in beta cell reserve and function [42]. In patients with established diabetes, insulin omission
(intentional, as a result of insulin pump failure or other technical problems, or related to lack
of access to medical care) is a major cause. Acute stress, commonly induced by an intercurrent
illness, might precipitate DKA. During stress, counterregulatory hormone (glucagon, cortisol,
growth hormone, and epinephrine) levels increase, causing hyperglycemia and an increased
requirement for insulin. If this increased need for insulin is not met, DKA may ensue. Fur‐
thermore, an acute illness may impair the child’s ability to replace fluid losses.
Insulin deficiency leads to hyperglycemia as a result of decreased utilization of glucose at the
same time of increased hepatic and renal glucose production. Hyperglycemia increases serum
osmolality, and in response, thirst is induced and osmotic diuresis occurs. The increased fluid
loss further promotes polydipsia. Because of the unavailability of glucose to tissues, compen‐
satory mechanisms are activated. Counterregulatory hormones are secreted, leading to
increased glucose production by gluconeogenesis and glycogenolysis [43]. Insulin resistance
increases and lipolysis is promoted, resulting in production of free fatty acids (FFAs). FFAs
are metabolized into ketone bodies, particularly β-hydroxybutyrate, by the liver as an
alternative energy source. The accumulation of ketones leads to metabolic acidosis. Another
result of the decreased insulin and elevated counterregulatory hormone levels is proteolysis
and reduced production of proteins. By this mechanism, substrates for gluconeogenesis are
added, further contributing to the hyperglycemia. Initially, plasma ketone body levels rise,
causing ketonemia and a base deficit; compensating mechanisms are activated and might lead
to measurement of a normal pH. As the condition progresses, ketones further accumulate,
ketonuria occurs, and eventually the metabolic acidosis becomes evident. The ketoacidosis
causes decreased bowel motility, particularly of the small bowl, accompanied by nausea and
vomiting. At this stage, the patient may be unable to compensate for the urinary fluid losses.
In a vicious cycle, dehydration impairs the renal ability to clear glucose and ketoacids, thus
further worsening the hyperglycemia and acidosis. The increasing osmolality, dehydration,
and acidosis decrease cerebral function. This might be manifested as lethargy, or even an
altered level of consciousness, further impairing the patient’s ability to rehydrate. At presen‐
tation, the degree of dehydration ranges from mild to severe, with the majority of children
presenting with moderate degrees of dehydration [44]. To compensate for the acidosis,
respiratory mechanisms are activated, causing the labored, rapid, deep breathing typically
described in patients with DKA (i.e., Kussmaul respirations). The acetone released in the breath
results in a characteristic fruity odor.
Serum hyperglycemia and hyperosmolarity together with the acidosis and osmotic diuresis
lead to significant electrolyte deficiencies and imbalances [40, 45, 46].
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3.1. Potassium depletion
Total body stores of potassium are depleted in basically every patient with DKA, and the
average potassium loss is 5 mmol/kg body weight. However, the serum potassium levels may
not reflect these losses, and the actual level may be low, normal, or even elevated, particularly
if renal function is impaired. The entry of hydrogen ions, accumulated extracellularly due to
the acidosis, into cells drives out the intracellular potassium. The osmotic diuresis together
with the high levels of aldosterone secreted as a result of the dehydration cause significant
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Figure 1. Pathophysiology of diabetic ketoacidosis.
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urinary loss of potassium. Emesis might cause further loss of potassium through the gastro‐
intestinal tract. However, an exception is patients with severe volume depletion, in whom
renal insufficiency may lead to hyperkalemia. During treatment of DKA, both the insulin itself
and the reversal of acidosis generate a net shift of potassium back into cells. Moreover, there
is some evidence suggesting a kaliuretic effect of insulin [47]. Altogether, these may result in
severe hypokalemia. Patients with hypokalemia at presentation likely suffer more severe total
body potassium depletion and are at particular risk of severe hypokalemia and cardiac
instability as treatment is provided.
3.2. Sodium and chloride depletion
The osmotic diuresis in DKA results in urinary loss of sodium, and the hyperosmolar state
drives water out of cells into the extracellular space, leading to dilutional hyponatremia. The
average sodium loss is 6 mmol/kg body weight. Chloride is secreted in the urine with sodium,
and the loss is on average 4 mmol/kg body weight. It should be kept in mind that the admin‐
istration of chloride during the treatment of DKA may lead to hyperchloremic metabolic
acidosis, thus interfering with the correction of acidosis.
3.3. Phosphate depletion
Phosphate shifted extracellularly by the acidosis is then lost in the urine. Phosphate losses can
be substantial and are estimated to be about 0.5–2.5 mmol/kg body weight. Significant
hypophosphatemia has the potential to impair oxygen delivery to tissues and cause muscle
weakness. However, despite very low serum levels of phosphate in some patients, such
complications are rare, and studies did not demonstrate a benefit for phosphorous replacement
[48, 49].
Beyond the electrolyte deficiencies described, in recent years, several studies have pointed
out that a deficiency of thiamine (vitamin B1), a water-soluble vitamin of the B complex,
may be clinically significant in patients with DKA. Thiamine deficiency was found to be
common in children with DKA and may worsen with treatment [50]. The role of this defi‐
ciency in the clinical presentation of DKA is yet to be revealed.
4. Clinical presentation and diagnosis of DKA
Metabolic decompensation in DKA usually develops over a period of hours to a few days.
Progression can be particularly rapid in patients with established diabetes. Misdiagnosis of a
patient with new-onset diabetes may lead to deterioration of the metabolic status. Particularly
in young children, misdiagnosis may be a result of the nonspecific symptoms and signs often
described in DKA. The earliest clinical manifestations of DKA are related to hyperglycemia
and may differ according to age, length of prodromal period, degree of acidosis, and volume
depletion [51, 52]. Symptoms and signs in DKA are most often related to the hyperglycemia,
dehydration, and acidosis [4, 53-55].
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4.1. Symptoms
• Polydipsia, polyuria, and/or nocturia are almost always present, although often not
reported.
• Nocturnal or daytime secondary enuresis is often described; polyphagia and weight loss
may occur.
• As a result of the acidosis, patients may suffer nausea, vomiting, abdominal pain, shortness
of breath, lethargy, or fatigue.
4.2. Physical signs
• Dehydration: Children with DKA often present with 5–10% fluid deficit [51, 56]. They may
lack the classical signs of hypovolemia and dehydration because of the acute and chronic
losses of both extracellular and intracellular water [57]. Findings depend on the degree of
dehydration and may include dry oral mucosa and decreased skin turgor, tachycardia, a
sunken fontanelle, and/or sunken eyes. Most patients are normotensive, although postural
hypotension can occur.
• Tachypnea or Kussmaul (deep, sighing, and labored) respiration with a fruity acetone odor.
• Signs of decreased tissue perfusion such as a slow capillary refill.
• Neurologic findings [58]: from confusion and drowsiness to decreased consciousness and
coma. Neurologic findings should raise the suspicion of cerebral edema.
In infants, especially those who are not toilet trained, the diagnosis may be delayed. Weight
loss, irritability, and decreased activity are common at presentation. Dehydration and severe
diaper rash may be the only physical signs. Older children and adolescents can manifest
profound wasting, cachexia, and prostration on DKA presentation, especially with a prolonged
course of uncontrolled/misdiagnosed diabetes.
4.3. Laboratory findings
4.3.1. Diagnostic criteria
Biochemical criteria for the diagnosis of DKA are defined as follows [40, 51, 56, 59]:
• Hyperglycemia: blood glucose (BG) >200 mg/dl (11 mmol/L)
• Metabolic acidosis: venous pH <7.3 and/or bicarbonate <15 mmol/L
• Ketonemia and ketonuria: serum beta hydroxybutyrate ≥3 mmol/L
On certain occasions, patients may present with “euglycemic ketoacidosis” where glucose
levels are near normal [54, 59]. This may develop in young children who consumed small
amounts of carbohydrates or are partially treated or in children with emesis.
The severity of DKA is established by the degree of acidosis: mild DKA, pH 7.2–7.3 or
bicarbonate <15 mmol/L; moderate DKA, pH 7.1–7.2 or bicarbonate 5–10 mmol/L; and severe
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DKA, pH <7.1 or bicarbonate <5 mmol/L [51, 56, 58]. The duration of symptoms, volume deficit,
degree of ketosis, and neurologic status further determine the severity of illness in a child with
DKA.
4.3.2. Acid–base balance
Acidosis is caused by the production and accumulation of ketones in the serum [49]. Three
ketones are produced in DKA: two ketoacids (beta-hydroxybutyrate and acetoacetate) and the
neutral ketone, acetone. In DKA, beta-hydroxybutyrate constitutes 75% of the circulating
ketones. During recovery, it is converted to acetoacetate and acetone, which persists for a
longer period. Therefore, measuring serum beta-hydroxybutyrate is the most useful for
diagnosis. The severity of the metabolic acidosis is dependent on the compensatory respiratory
alkalosis, the acid excretion in the urine [60], and the duration and rate of increased ketoacid
production. The serum anion gap (AG) is an index of unmeasured anions in the blood (normal
in children is 12 ± 2 mEq/L). Most patients with DKA present with a high AG (≥20 mEq/L) due
to high serum levels of ketoacids. The resolution of ketoacidosis is followed by a normal AG.
4.3.3. Electrolyte imbalances
Laboratory tests that should be routinely monitored in the setting of DKA include serum
glucose, electrolytes, creatinine and BUN, blood gases, pH, bicarbonate, and a complete blood
count. Changes over time in electrolytes and renal function tests must be followed.
Serum potassium: As mentioned earlier, potassium loss can be a result of increased ketoacid
excretion, osmotic diuresis, vomiting, or diarrhea. The serum potassium concentration may
be normal, increased, or decreased at diagnosis of DKA. However, monitoring of potassium
levels is crucial because hypokalemia may eventually develop.
Serum sodium: Low serum sodium in DKA may occur due to hyperglycemia and its effect on
plasma osmolarity. Polydipsia and excessive consumption of water can also contribute to
lowering sodium concentration. Osmotic dieresis and water loss in excess of sodium and
potassium will tend to raise the serum sodium concentration. Hyperlipidemia can cause
pseudohyponatremia [61].
Serum phosphate: Decreased phosphate intake and phosphaturia may result in a negative
phosphate balance. At presentation of DKA, serum phosphate is usually normal or high due
to the combined effect of metabolic acidosis and insulin deficiency. The degree of phosphate
loss in DKA is apparent after insulin treatment [62].
4.4. Differential diagnosis of DKA
DKA should be differentiated from other causes of acidosis and/or hyperglycemia, such as
acute gastroenteritis with metabolic acidosis, uremia, salicylate intoxication, starvation ketosis
and lactic acidosis. When the presenting symptom is altered consciousness or coma, encepha‐
litis and other CNS pathologies must be ruled out. Diabetic ketoacidosis should also be
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distinguished from the hyperosmolar hyperglycemic state, which is infrequent in children [51,
57, 63]. The main differences between these conditions are the degree of acidosis and insuli‐
nopenia.
5. DKA treatment in children
Successful treatment of DKA requires correction of dehydration, acid–base and electrolyte
imbalances, insulin administration, and identification of comorbid and precipitating condi‐
tions. This treatment may be associated with inherent risks of inducing hypoglycemia,
hypokalemia, and cerebral edema. Therefore, any protocol must be used with caution, and
close monitoring of patients is crucial. Children with severe DKA, an altered level of con‐
sciousness, or those who are at increased risk for complications should be considered for
treatment in an intensive care setting. In this chapter, we will focus on the general principals
and considerations in DKA management as well as controversies regarding DKA treatment.
5.1. Standard protocols for DKA management
There is some variability in protocols for DKA management, but the basic principles are similar
in the various protocols available in the literature [40, 51, 64, 65]. Protocols enabling stand‐
ardization of treatment are of great value to the treating team involved; however, clinical
judgment should always be practiced. Frequent monitoring of the patient is a very important
aspect of the treatment and should include meticulous documentation of clinical observations,
fluid balance, laboratory results, and medications administered. A neurological follow-up for
warning signs and symptoms of cerebral edema is also essential.
5.2. Fluid replacement
Fluid replacement in children with DKA remains a controversial topic with regard to the
amount of intravenous fluid, rate of delivery, and fluid composition. Current recommenda‐
tions are based on expert consensus statements and accumulated clinical experience, as
evidence from large randomized clinical trials is lacking.
5.2.1. First hour fluid resuscitation
The goals of initial volume expansion are to restore the effective circulating volume and the
glomerular filtration rate. Intravenous fluid administration bares the risk of inducing an
elevation in the intracranial pressure (ICP), potentially resulting in cerebral edema, and thus
should be done carefully [66, 67]. In a rabbit model of DKA, the use of hypotonic fluids,
compared with isotonic, was associated with greater rises in ICP [66]. Some studies suggest
that rapid fluid replacement may increase the risk of cerebral edema [68, 69], although other
studies did not support this finding [70, 71]. Studies in both adults and children demonstrated
a more rapid correction of acidosis when a slower rate of fluid administration with isotonic or
near-isotonic solutions was used [72, 73]. Hyperchloremic metabolic acidosis is another often
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overlooked risk resulting from the use of large volumes of normal saline (NS) (0.9%) [73, 74].
At present, there is no data that support the use of colloid in preference to crystalloid in the
treatment of DKA. Based on these data, most protocols recommend an initial IV infusion of
10–20 ml/kg of normal saline (NS) (0.9%) or Ringer’s lactate over the first 1 to 2 h of treatment.
Fluid boluses may be repeated according to the patient’s hemodynamic status. However, total
IV fluids should not exceed 40 ml/kg in the initial 4 h of treatment due to the aforementioned
risks.
5.2.2. Fluid replacement over the next 24–48 h of treatment
Once the child is hemodynamically stable, subsequent volume expansion should be given
more gradually, with a goal of replacing the remaining fluid deficit over the next 24 to 72 h.
Significant additional fluid loss after initiation of treatment is rare because vomiting and
excessive urine output usually resolve within the first hours of treatment. Half NS or NS (0.45–
0.9%) solutions are appropriate for replacement. The rate of fluid administration is guided by
the estimated degree of dehydration and fluid deficit. Calculating the effective osmolality is
also of use, and most often, replacement is in the range of 1.5–2 times the usual maintenance
requirement based on age and weight. Unless a contraindication exists, potassium must be
added at this time (see below). To prevent a rapid decrease in plasma glucose concentration
and hypoglycemia, 5% glucose should be added to the IV fluid when the plasma glucose falls
to approximately 250–300 mg/dl (14–17 mmol/L), or sooner if rapidly decreasing. Fluids that
were given in another facility before assessment should be factored into calculation of deficit
and be subtracted from the 24-h totals.
5.3. Insulin administration
5.3.1. Intravenous insulin administration
Insulin therapy is essential to suppress lipolysis and ketogenesis and to correct acidosis. Insulin
infusion is recommended 1–2 h after starting fluid replacement therapy and initial volume
expansion. An initial IV bolus of insulin is unnecessary, it was not shown to affect the duration
of time to attaining a serum glucose level of less than 250 mg/dl, yet it may increase the risk of
cerebral edema [69, 75, 76]. A slow infusion of a low dose of 0.1 U/kg/h IV insulin is considered
the standard of care in pediatric DKA [77, 78]. The dose of insulin should remain 0.1 U/kg/h
at least until the resolution of DKA (pH >7.30; bicarbonate >15 mmol/L and/or closure of the
anion gap). It is possible that even a lower dose of insulin is sufficient for DKA treatment. A
recent randomized control trial compared a very low dose IV insulin infusion (0.05 U/kg/hr)
to the standard dose. Similar results were achieved in terms of the rate of blood glucose
decrease and the resolution of acidosis, suggesting that a dose lower than the current standard
dose can be used [78].
5.3.2. Subcutaneous insulin regimens
Few studies, mostly in adults, demonstrated subcutaneous rapid acting insulin injected every
1–2 h to be a valid alternative for the standard intravenous insulin treatment of mild-to-
moderate uncomplicated DKA [79, 80]. In our practice, we administer subcutaneous regular
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insulin (SCRI) every 4 h for treating children with DKA and pH ≥7.00 and K >2.5 mEq/L. Insulin
therapy is initiated during the second hour of treatment and administered every 4 h until
resolution of DKA. The insulin dose is calculated as 0.8–1 IU/kg/day divided by 6. This
treatment was found to be a simple, effective, and safe alternative to the standard DKA
protocol. Such treatment has the potential to simplify insulin administration and reduce both
patient inconvenience and admission costs. Subcutaneous insulin should not be used in
subjects whose peripheral circulation is impaired.
5.4. Electrolyte replacements
5.4.1. Potassium replacement
Children with DKA suffer from total body potassium deficits of approximately 3–6 mmol/kg.
Hypokalemia at presentation may be related to prolonged duration of disease, whereas
hyperkalemia primarily results from reduced renal function [60]. Insulin administration and
the correction of acidosis drive potassium back into the cells, which may cause hypokalemia
and predispose the patient to cardiac arrhythmias. Replacement therapy is usually required
regardless of the serum potassium concentration. In most protocols, potassium is not given
during the first hour of fluid resuscitation unless the patient is hypokalemic, in which case
some protocols recommend adding potassium to the initial volume expansion before starting
insulin therapy. Potassium can be given as potassium phosphate or potassium chloride. The
starting potassium concentration in the infusate should be 40 mmol/L. Subsequent potassium
therapy should be based on serum potassium measurements.
5.4.2. Phosphate and calcium replacement
Prospective studies have not shown clinical benefit from phosphate replacement [48, 49, 81].
The deficit usually corrects spontaneously, although it should be kept in mind that it may
persist for several days after the resolution of DKA [45]. Therefore, only severe and sympto‐
matic hypophosphatemia accompanied by significant weakness should be treated with
phosphate supplements. Potassium phosphate may be used safely in combination with
potassium chloride or acetate to avoid hyperchloremia. Careful monitoring of serum calcium
should be performed to avoid hypocalcemia. In a study on nine children with DKA, during
phosphate infusion, transient hypocalcemia occurred in 67% and transient hypomagnesemia
in 56%. One child developed carpopedal spasms refractory to intravenous infusion of calcium
gluconate but responsive to intramuscular injection of magnesium sulfate. In 33%, parathyroid
hormone was low at the time of hypocalcemia, an observation that suggests transient hypo‐
parathyroidism [82].
5.4.3. Bicarbonate therapy
Acidosis is reversible by insulin replacement. Several clinical trials have shown no clinical
benefit from bicarbonate administration in pediatric DKA [83-86]. Moreover, bicarbonate
therapy may cause paradoxical CNS acidosis. Bicarbonate crosses the blood–brain barrier
slowly, yet the CO2 formed (HCO3 + H+ →H2O + CO2) crosses rapidly into the CNS forming
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H2CO3, thus worsening the CNS acidosis [87, 88]. As a result of the sodium supplement
included in the bicarbonate preparations, this therapy may be associated with hypokalemia
and increasing osmolality. Bicarbonate administration was also reported as a risk factor for
cerebral edema in several studies [51, 69, 89]. Despite all the risks mentioned, in must be kept
in mind that patients with severe acidemia (arterial pH ≤6.9) in whom decreased cardiac
contractility and peripheral vasodilatation can further impair tissue perfusion and patients
with life-threatening hyperkalemia may benefit from cautious alkali therapy [84]. If bicarbon‐
ate is considered necessary, it should be cautiously administered at a dose of 1–2 mmol/kg
over 60 min.
5.5. Introduction of oral fluids and transition to SC insulin injections
Upon resolution of DKA and when substantial clinical improvement has occurred, oral fluids
can be introduced and a protocol of subcutaneous insulin can be initiated or restarted.
6. Complications of pediatric DKA
As mentioned in detail earlier, diabetic ketoacidosis (DKA) is treated with fluids, electrolytes,
and insulin. With prompt treatment, complications of DKA are uncommon. However, when
complications do occur, they are usually serious with significant mortality and long-term
morbidity. Surprisingly, the most common complication of DKA (cerebral edema) may be
related to this lifesaving treatment.
6.1. Cerebral edema
Cerebral edema is a devastating and unpredictable complication of DKA and its treatment.
Epidemiological studies demonstrate that overall cerebral edema occurs in around 7/1000
episodes of DKA and is more common in children and newly diagnosed patients. Other studies
found that clinically apparent cerebral edema develops in 1–2% of children with DKA [90].
The pathophysiology of cerebral edema is not well understood, and it is likely that several
processes contribute to the development of this complication: ischemic, osmotic, and vaso‐
genic.
Osmotic: ultimately, cerebral edema is due to excessive entry of water into the cells of the central
nervous system due to the presence of intracellular idiogenic osmoles causing swelling of the
brain as serum osmolality drops during treatment.
Vasogenic: studies using magnetic resonance diffusion weighted imaging demonstrate that the
apparent diffusion coefficient of brain water is greater during treatment of DKA than during
recovery, indicating increased extracellular fluid due to an increase in blood brain barrier
permeability during the acute treatment phase of DKA [91-93]. These findings are consistent
with the vasogenic cerebral edema, i.e., fluid surrounding the cells, rather than osmotic cell
swelling that has previously been suggested. This vasogenic theory is also supported by the
fact that the degrees of dehydration and hyperventilation at presentation, but not initial
osmolality or osmotic changes during treatment, were correlated with degree of edema
Diabetic Ketoacidosis in the Pediatric Population with Type 1 Diabetes
http://dx.doi.org/10.5772/60592
107
formation [92]. This edema (within the enclosed space of the cranium) can cause transtentorial
brain herniation through the foramen magnum, leading to unconsciousness and respiratory
arrest.
6.1.1. Risk factors for cerebral edema
Several case–control studies have pointed out risk factors for the development of cerebral
edema [69, 70, 94, 95]. These can be divided into two main groups.
Risk factors related to disease severity at presentation:
a. Younger age
b. Newly diagnosed compared with established diabetes
c. More severe acidosis at presentation
d. Higher serum urea levels
e. Lower partial arterial CO2 (PaCO2) values
Risk factors related to therapy:
a. Larger volume of fluid given during the first 4 h of treatment
b. Administration of bicarbonate
c. Lower plasma sodium concentrations
d. Administration of insulin within the first hour of treatment
6.1.2. Symptoms and signs
These typically appear within 6–24 h after starting intravenous fluids and insulin treatment.
Therefore, it is crucial to monitor and recognize the early warning signs of cerebral edema
through careful monitoring of all DKA patients. These include signs and symptoms of
increasing intracranial pressure, such as a decline in the level of consciousness, headaches,
bradycardia, depressed respiration and apnea, papillary changes, papilledema, posturing,
seizures, and coma.
6.1.3. Diagnosis
The diagnosis of cerebral edema is clinical. Recognition of the above-mentioned signs and
symptoms should allow early intervention and hopefully prevention of morbidities associated
with this condition. CT or MRI of the brain should be performed to rule out other diagnoses
and potentially confirm the diagnosis of cerebral edema. However, it should be emphasized
that radiographic imaging may be unhelpful in detecting cerebral edema if performed very
early after the development of symptoms.
6.1.4. Treatment of cerebral edema
The patient should be treated and monitored in the intensive care unit; however, if located
elsewhere, initial treatment must not be delayed until transitioned. Mannitol or hypertonic
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saline should be readily available for use at the earliest signs and symptoms of cerebral edema.
Other measures include a reduction in the rate of fluid administration and elevation of the
head of the bed. Mannitol 1 g/kg (5 ml/kg of mannitol 20%) should be administered over 15
min; alternatively, hypertonic saline (3% NaCl) 5–10 ml/kg over 30 min can be administered.
This treatment will reduce brain edema and blood viscosity and improve cerebral blood flow.
Intubation and ventilation may be necessary to provide adequate ventilation and correct
acidosis. Aggressive hyperventilation has been associated with poor neurological outcome
and is not recommended [96].
6.2. Hypoglycemia and hypokalemia
These are additional potential complications of DKA treatment. Both are discussed earlier in
the chapter.
6.3. Rare complications of DKA
6.3.1. Adult respiratory distress syndrome
This has been reported in patients with DKA, especially in patients younger than 50 years.
Clinical features include dyspnea and tachypnea, with central cyanosis and nonspecific chest
symptoms.
6.3.2. Acute renal failure
This can develop due to severe dehydration. Once fluid replacement is restored, kidney
function should start to recover.
6.3.3. Thromboembolic complications
These may arise as a consequence of dehydration, increased blood viscosity, and coagulability.
Rehydration and restoration of body fluids might help in preventing these complications [97].
Established thromboembolic complication should be treated promptly.
7. Prevention of pediatric DKA
The best approach for decreasing the burden of DKA is prevention. Preventive measures are
based on the identified risk factors of T1DM and DKA and on their clinical presentation. Risk
factors differ between DKA at the time of T1DM diagnosis and episodes occurring in patients
with established diabetes. Identifying high-risk children, using both immunologic and genetic
methods, can lead to earlier diagnosis of diabetes and decreased DKA incidence at disease
onset [10, 33, 98, 99]. However, such screening raises obvious ethical questions, as the exact
risk or timing of the development of diabetes in a child at risk are not known and no treatment
has proved protective thus far. In families with T1DM, a special attention to early symptoms
and signs is recommended to detect the onset of diabetes in other members and to prevent
future DKA [51].
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Greater public awareness to signs and symptoms of DKA has been related to decreased rates
of DKA. This is further emphasized by the success of awareness campaigns in decreasing the
rates of DKA. A campaign to increase awareness of physicians, schools, and parents was
carried out in Parma, Italy [1991–1997] [100, 101]. The researchers displayed posters in pediatric
centers, schools, and physician offices and demonstrated a significant reduction in the DKA
rate from 78% to 12% in 6–14 years old children over an 8-year period. An Australian study
demonstrated a reduction in DKA prevalence in new-onset diabetes from 38% to 14%, when
repeating the Parma study diabetes awareness campaign [102]. However, it is important to
mention that not all such programs have been successful [5], and complex risk factors might
be involved.
The rates of DKA in patients with established diabetes can also be reduced. Identifying the
specific causes for recurrent DKA in a child is important and may prevent future DKA events
[40]. Detailed and intensive diabetes education programs, telephone help lines, and availability
of skilled health care providers can reduce DKA occurrence [103-106]. Education programs
lead to better understanding of the disease and might assist families in identifying times of
increased risk (i.e., intercurrent illness or pump malfunction) as well as early signs of deteri‐
oration and of DKA. Such programs are important to the noncompliant children, especially
those with recurrent episodes of DKA, and should be led by professional teams [17, 107].
Education and adult guidance were shown to decrease insulin omission in patients with
recurrent DKA episodes [108]. Early identification of ketosis, using home measurement of beta-
hydroxybutyrate, can prevent progression to DKA [109].
8. Conclusion
DKA is a serious complication of pediatric T1DM. The pathophysiology is complex, demon‐
strating reciprocal effects between the metabolic derangements involved. A “hunger” response
takes place despite the abundance of metabolic substrate. Various risk factors have been
identified, some are patient related yet others emphasize the important effects of both family
and social circumstances. DKA is largely preventable, and efforts to further increase awareness
to this complication of diabetes should be encouraged.
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